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ABSTRACT 
Objectives: We assessed whether a wheat bran extract (WBE) containing arabinoxylan 
oligosaccharides (AXOS) elicited a prebiotic effect and modulated gastrointestinal parameters 
in healthy preadolescent children upon consumption in a beverage. 
Methods: This double-blind, randomized, placebo-controlled, crossover trial evaluated the 
effects of consuming WBE at 0 (control) or 5.0 g/day for 3 weeks in 29 healthy children (8-12 
years). Faecal levels of microbiota, short-chain fatty acids, branched chain fatty acids, 
ammonia, moisture and faecal pH were assessed at the end of each treatment and at the end of 
a one-week run-in period. In addition, the subjects completed questionnaires scoring distress 
severity of 3 gastrointestinal symptoms. Finally, subjects recorded defecation frequency as 
well as stool consistency. 
Results: Nominal faecal bifidobacteria levels tended to increase after 5 g/day WBE 
consumption (p = 0.069), whereas bifidobacteria expressed as percentage of total faecal 
microbiota was significantly higher upon 5 g/day WBE intake (P = 0.002). Additionally, 5 
g/day WBE intake induced a significant decrease in faecal content of isobutyric acid and 
isovaleric acid (P < 0.01), markers of protein fermentation. WBE intake did not cause a 
change in distress severity of the 3 surveyed gastrointestinal symptoms (flatulence, abdominal 
pain/cramps, urge to vomit) (P > 0.1).  
Conclusions: WBE is well tolerated at doses up 5 g/day in healthy children. In addition, 
intake of 5 g/day exerts beneficial effects on gut parameters, in particular increase of faecal 
bifidobacteria levels relative to total faecal microbiota, and reduction of colonic protein 
fermentation.  
Key Words: Wheat Bran Extract, arabinoxylan oligosaccharides (AXOS), prebiotic, protein 
fermentation reduction, children 
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INTRODUCTION 
Wheat Bran Extract (WBE), a food-grade, fiber-rich, water-soluble preparation that is 
produced by enzymatic extraction from wheat bran, is highly enriched in arabinoxylan-
oligosaccharides (AXOS). AXOS consist of a backbone of β-1,4-linked D-xylopyranosyl 
residues (xylose), some of which are mono- or di-substituted at the C(O)2 and/or C(O)3 
position with α-L-arabinofuranosyl residues (arabinose)(1). Some of the xylose units in the 
backbone of AXOS carry glucuronic acid at the C(O)2 position, whereas some of the 
arabinose units are ester-linked at the C(O)5 position with ferulic acid(1). The AXOS in WBE 
form a heterogeneous mixture of oligosaccharides differing in degree of polymerization and 
degree of substitution of the xylan backbone. Besides AXOS, WBE contains up to 15% 
glucans [mainly β-D-(1,3)(1,4)-linked glucan oligomers] and low levels (< 2%) of proteins, 
minerals and monosaccharides(2).   
AXOS are non-digestible fermentable prebiotic oligosaccharides with bifidogenic activity as 
was demonstrated in in vitro studies(3), animal studies (chicken(4,5), rats(6)) and clinical trials 
with healthy adults(7-9). The evidence for AXOS having prebiotic activity has been recently 
reviewed(1). In addition, AXOS consumption decreases the excretion of urinary and faecal p-
cresol, a marker of intestinal protein fermentation(7,8,10). Colonic protein fermentation is often 
regarded as detrimental to host health, in particular with respect to colon toxicity, 
mutagenicity and carcinogenicity(11). Proteolytic fermentation leads to the production of 
potentially toxic compounds such as phenolic compounds, sulfur-containing compounds, 
amines and ammonia (12-14). The toxicity of these protein fermentation metabolites has mainly 
been established in in vitro studies(15-17) and animal studies(18,19). 
Until date, the gastrointestinal effects of and tolerance effect to WBE in humans has only 
been investigated in adult volunteers. It is known that the composition of gut microbiota in 
preadolescent and adolescent children differs from that of adults(20,21), with notably a higher 
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abundance of Bifidobacteria in teenage children versus adults(21).  The purpose of this study 
therefore was to evaluate the effect of intake of 5 g/day WBE on gastrointestinal health 
parameters in healthy preadolescent children aged 8-12 years. The effect of WBE 
administration on colonic carbohydrate fermentation was investigated through measurement 
of faecal levels of SCFAs and the effect on colonic protein fermentation was analyzed 
through measurement of faecal levels of isovaleric acid and isobutyric acid. Since WBE is 
intended to be added to food products, including food products for children, it is also 
important to assess tolerance to the product and its safety profile. Tolerance to WBE was 
assessed through self-reported scoring by the children of distress severity of the following 
three gastrointestinal symptoms: flatulence, abdominal pain/cramps and urge to vomit. Safety 
was evaluated by assessing the occurrence of adverse events (AEs).  
 
MATERIALS AND METHODS 
Study design 
Figure 1 presents a schematic overview of the randomized, placebo-controlled, double-blind, 
cross-over study. The study started with a one-week run-in period, followed by two 3-weeks 
treatment periods, during which the children had to take in placebo or 5 g/day WBE,  with a 
2-weeks wash out period in between the treatment periods. The WBE dose of 5 g/day was half 
the WBE dose that was shown in a previous trial performed on adults to raise the levels of 
Bifidobacteria(8), taking into consideration the lower average body weight of preadolescent 
children versus adults. WBE and placebo were administered as non-carbonated soft drinks of 
which the volunteer drank daily 70 ml after breakfast and 70 ml after dinner (140 ml per day 
in total). The WBE-containing soft drinks contained sucrose, colorant, flavor, citric acid and 
potassium sorbate. The placebo soft drink had the same composition as the WBE-containing 
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soft drink, except that WBE was omitted and that 0.25 g/l tricalcium phosphate was added to 
mimic the turbidity of the WBE-containing soft drinks. Subjects were randomly assigned to 
one of two randomization groups, differing in the treatment sequence by which the two types 
of drinks were to be consumed. The investigators who had direct contact with the subjects 
were blinded to the treatment since they were unaware of the randomization groups to which 
the subjects were assigned. Moreover, the appearance and the taste of the different soft drinks 
were near-identical, and the two types of soft drinks could not be discriminated from each 
other without careful side-to-side comparison. Side-to-side comparison of the drinks by the 
volunteers was not possible as only one drink type was supplied prior to each treatment 
period.  
Study population 
A total of twenty-nine healthy children (11 girls and 18 boys, all of Caucasian ethnicity) 
participated. Exclusion criteria were extreme dietary habits in the 6 weeks before the start of 
the trial, intake of antibiotics in the 3 months before the start of the trial, intake of medication 
or dietary supplements influencing gastrointestinal tract processes in the 2 weeks before the 
start of the trial, abdominal surgery in the past (with exception of appendectomy), chronic 
diseases/conditions, serious illness in the 3 months before the start of the trial, complete 
anaesthesia in the month before the start of the trial, history of chronic gastrointestinal (GI) 
conditions such as inflammatory bowel disease and irritable bowel syndrome, allergy to wheat 
products and celiac disease.  
During the study, the intake of food substances containing probiotics and/or prebiotics was 
forbidden. The children and their parents were asked to read food labels carefully to check for 
absence of pro- and/or prebiotics. This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures involving human subjects were 
approved by the Ethics Committee of the University Hospital UZ Leuven (Belgium) under 
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approval number ML5282. Written informed consent was obtained from all children and their 
parents. The trial is registered in the clinicaltrials.gov register (NCT01001949). 
Test product 
Wheat Bran Extract (Brana Vita® 200) was produced from wheat bran by Fugeia NV 
(Leuven, Belgium), using a procedure based on that described previously(22). WBE was 
analyzed for AXOS content, AXOS average degree of polymerization (avDP), 
arabinose/xylose ratio (A/X ratio), bound ferulic acid and glucuronic acid, glucose as part of 
poly/oligosaccharides, mannose as part of poly/oligosaccharides, galactose as part of 
poly/oligosaccharides, free monosaccharides, moisture, protein and ash by analytical 
procedures outlined previously(2). Table 1 shows the composition of the WBE preparation 
used in the present study. It consisted of 79.0% AXOS (on dry matter basis), and the AXOS 
had an avDP of 5 and an A/X ratio of 0.19. 
Biochemical and microbiological analyses of faecal samples 
On the evening of day 5 or during day 6 of the run-in period as well as on the evening of day 
19 or during day 20 of each treatment period, one single stool was collected by each child. 
Faecal samples were analyzed for microbiota composition using FISH analysis. Processing of 
paraformaldehyde fixed samples and FISH analysis to quantify Bifidobacteria, the 
Lactobacillus/Enterococcus group, the Clostridium histolyticum/lituseburense group, the 
Faecalibacterium prausnitzii group and the Roseburia/Eubacterium rectale group was 
performed as described previously(8). Concentrations of the short-chain fatty acids (SCFAs) 
acetate, propionate, butyrate and of the branched chain fatty acids (BCFAs) isovaleric acid 
and isobutyric acid were determined as described(23), using 2-methylhexanoic acid as internal 
standard. To determine the faecal pH, an aliquot of approximately 1 g faeces was 
homogenized by mixing with demineralized water (final concentration 10% (w/w)) (24). The 
pH was measured immediately upon homogenization. Ammonia levels were measured on the 
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same faecal slurries as used for pH determination, following the procedure described 
previously(25). 
Recording of gastrointestinal symptoms and stool parameters 
Gastrointestinal symptoms were monitored daily during the run-in period and the last week of 
each treatment period. The volunteers were asked to grade the distress severity of abdominal 
pain/cramps, flatulence and urge to vomit using a 5-step scale ranging from no (0), minimal 
(1), mild (2), moderate (3) to severe (4) distress(7). During the run-in period and the last week 
of each treatment period, the number of stools as well as stool consistency according to the 
Bristol Stool Form Scale(26) were recorded daily. The average stool frequency was calculated 
as the number of stools divided by the number of days of diary recording, the average stool 
consistency as the sum of Bristol Stool Form Scales divided by the number of stools, and the 
composite parameter of stool frequency and consistency (called Bristol composite measure) as 
the sum of Bristol Stool Form Scales divided by the number of days of diary recording(8,27). 
Recording of Adverse Events (AEs) and treatment compliance 
At the end of the run-in period and after each intake period, the children were asked to record 
whether they had suffered from a medical condition, had to take in medication, or had 
incidentally taken prebiotics or probiotics. Additionally, at each clinic visit, the children were 
asked these questions. This information was recorded in the appropriate section of the Case 
Report Form. Treatment compliance was defined as the number of times per treatment period 
that a serving of soft drink was not consumed. During each intake period, the children had to 
report daily whether they consumed the soft drinks after breakfast and after dinner.  
Statistical analyses of efficacy variables 
In order to test for differences at baseline, the treatment sequence groups were compared with 
respect to age, gender, faecal Bifidobacteria content and stool frequency. Comparison of the 
groups was based on a one-way analysis of variance (ANOVA) and a Chi-square test in case 
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of gender. The Fisher exact test was used if the chi-square test was judged inappropriate due 
to small cell sizes. When ANOVA analysis could not be used, the groups were compared 
using the non-parameteric Kruskal-Wallis test and pairwise using the Mann-Whitney U test. 
For each efficacy variable, the difference between both treatments was analyzed within the 
statistical model. A mixed model was used to capture the intra-volunteer correlation due to the 
repeated measurements for each volunteer. The treatment effect for the different parameters 
was analyzed using a linear mixed model(28). The models were estimated using the nlme 
package from R's base distribution(29). The fitted model included subject as a random effect 
and contained terms for treatment and treatment sequence. Additionally, the results of the run-
in period were included as covariate in the linear mixed model. All tests of significance were 
performed at α = 0.05 and were two-sided, unless otherwise stated. Assumptions of normality 
of residuals were investigated for each variable using the Shapiro-Wilk test(30). When the data 
were normally distributed, linear mixed models were applied to the raw data as such, except 
for the microbiota data which were log transformed prior to analysis. When the distribution of 
the data was not approximated by a normal curve, values were ranked before analysis and the 
linear mixed model was performed on the rank-transformed data(31). Ties occurring during the 
rank-transformation were replaced by their average rank. The data to estimate the fixed effect 
parameter for the run-in of the response remained unranked.  
Evaluations of the effects of treatment on the efficacy variables were completed on an 
efficacy evaluable (EE) population, defined as all randomized subjects who received placebo 
and at least one serving of WBE containing soft drink and who provided at least one post-
randomization outcome data point during each of the two treatment phases. The per-protocol 
(PP) population was defined as the subset of EE subjects who completed the study, did not 
take excluded medications (e.g. antibiotics) or products and had no major protocol violations. 
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In the present study the PP population coincided with the EE population, and statistical 
analyses were not repeated for the PP population. 
Treatment effects as well as treatment by treatment sequence interaction effects were tested 
with linear mixed models using conditional F- and t-tests(28) (significance at α = 0.1). The 
single-step Tukey post-hoc multiple comparison procedure was used for the pairwise 
comparisons of the treatments, using R’s multcomp package(32). In case no significant 
interactions were found, treatment differences were evaluated based on the main effect model. 
In case of significant interactions, treatment differences were evaluated within each treatment 
sequence group (results not shown). Next to that, the overall differences were also analyzed 
by aggregating over the interaction effects, which was performed by setting up a linear 
combination of the treatment differences for each treatment sequence group, giving equal 
weights to both treatment sequence groups. For the distress severity of the 3 gastrointestinal 
symptoms, an analysis was performed using binary data. Although the symptoms were scored 
daily during one week on an ordinal scale and were subsequently aggregated (averaged) over 
the 7 days, lack of variation in the symptom scores obliged us to use binary response models. 
In this case, all volunteers who indicated for an aggregated gastrointestinal symptom score 
“no distress” were regarded as “0”. All persons who indicated an aggregated distress severity 
score differing from “no distress” were regarded as “1”. The level of the Clostridium 
histolyticum/lituseburense group was in a large proportion of the volunteers below the 
detection limit (log10 5.65 per g wet faeces), leading to a binary distribution of this dataset 
(“1” = content of Clostridium group ≥ log10 5.65 per g wet faeces; “0” = content of 
Clostridium group < log10 5.65 per g wet faeces). For the analysis of binary data, a 
generalized linear mixed-effects was used as described previously(8).  
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Statistical analysis of safety parameters and treatment compliance 
The safety population was defined as all randomized subjects who received at least one 
serving of WBE. Safety was analyzed using the emergent AEs in the safety population. An 
AE was attributed to the treatment period during which the AE started. An AE that started 
during a wash out period was attributed to the treatment preceding the specific wash out 
period. McNemar’s test was used to compare differences in AE frequencies among the two 
treatments (α = 0.025, Sidak correction for 2 comparisons)(33). Statistical analysis of the 
number of non-consumed SSD servings was performed using a Poisson mixed effect model 
with similar fixed effects as for the efficacy variables but excluding the runin period as there 
were no consumptions at runin. For the analysis of Poisson data, a generalized linear mixed-
effects model(34) with log link function was used with equal random and fixed effects as in the 
linear mixed model. For the Poisson data, a similar approach as for the continuous data was 
used starting from a basic model which contained the main effects: the value at baseline, 
treatment and treatment sequence. The test for a significant interaction between treatment and 
treatment sequence was done based on a likelihood ratio test(34). P-values were obtained 
similarly as described for the models of the the efficacy variables. Evaluation of a significant 
treatment effect was done by comparing the basic model to a model containing only treatment 
sequence and run-in. Adding and evaluating the interaction effects was done stepwise by 
adding treatment sequence based on the most significant likelihood ratio test. In case of not 
enough data in each interaction cell (<4), the final model to evaluate the treatment was the 
basic model and interactions were disregarded. For models with interaction effects and 
inflated standard errors of the treatment differences, the model containing only main effects 
was referred to. 
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RESULTS 
Study population 
The disposition of all study participants is presented in Figure 2. A total of 30 children were 
screened and 29 were randomized to the 2 different randomization groups. Since all children 
received WBE, the 29 children were included in the safety population. Of these, one child was 
excluded from the Efficacy Evaluable (EE) population since no data points were obtained 
from this volunteer during the placebo treatment. Hence, the EE population consisted of 28 
children. Since none of them had to take in antibiotics and all children were compliant, 
therefore, the Per Protocol (PP) was the same as the EE population. 
Baseline characteristics for the EE/PP population are presented for both randomization groups 
in Table 2. No significant differences could be observed at baseline between both 
randomization groups with respect to gender, age, stool frequency and faecal bifidobacteria 
level.  
Treatment compliance 
The number of times per treatment period that the volunteers of the PP population did not take 
in a serving of soft drink was on average very low (2.0% during the placebo intake period and 
1.8% during the WBE-intake period) indicating a good compliance to the study based on self-
reporting by the volunteer. No statistically significant differences (P > 0.1) were observed 
between the treatments. None of the volunteers reported that they had incidentally taken in 
prebiotics or probiotics during the study. Hence, overall compliance to the study was 
considered to be good. 
Adverse Events 
Adverse Events (AEs) were categorized in 6 categories according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (v3.0) prior to the unblinding of 
the study. During the run-in period, placebo intake period and WBE intake period, 4, 7 and 5 
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AEs occurred, respectively. Statistical analysis of the AEs in the safety population revealed no 
difference between the placebo and WBE treatment in frequency of any of the different AE 
categories (P > 0.1). 
Analysis of efficacy variables 
Conditional F-tests showed overall WBE-related significant treatment effects for 5 parameters 
(Table 3): faecal levels of bifidobacteria, percentage of bifidobacteria in faeces, faecal levels 
of isobutyric acid, faecal levels of isovaleric acid and faecal levels of total BCFAs (P < 0.1). 
The main results of the subsequent pairwise comparisons of these parameters will be 
discussed below. 
Levels of faecal microbiota 
In the PP population, WBE intake selectively increased bifidobacteria levels in the faeces 
(Table 3). Intake of 5 g/d WBE tended to increase the levels of bifidobacteria in the faeces 
relative to placebo intake by 0.19 log units (P = 0.069). The percentage of Bifidobacteria 
relative to the total bacterial content in faeces upon 5 g/d WBE intake increased by 1.7-fold 
relative to placebo intake (P = 0.002). The faecal levels of the other bacterial groups analyzed, 
the Lactobacillus/Enterococcus group, the Clostridium histolyticum/lituseburense group, the 
Faecalibacterium prausnitzii group and the Roseburia/Eubacterium rectale group, remained 
unchanged after WBE intake.  
Biochemical parameters in faeces 
Intake of 5 g/d WBE decreased the level of total faecal BCFAs and the levels of isobutyric 
acid and isovaleric acid by about 28% relative to placebo intake (P < 0.05) (Table 3).  
WBE intake did not affect the percentage moisture in faeces, nor did it influence faecal 
ammonia levels, faecal SCFAs levels and faecal pH (P > 0.1). 
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Bowel habits: defecation frequency and stool consistency 
WBE intake did not influence the number of bowel movements per day, nor did it modulate 
stool consistency as measured using the Bristol Stool Form Scale (P > 0.1).  
Analysis of tolerance variables 
Tolerability was assessed through self-reported scoring by the children of the distress severity 
of flatulence, urge to vomit, and abdominal pain/cramps, using a 5-step scale ranging from no 
(0), minimal (1), mild (2), moderate (3) to severe (4) distress. In Table 4, an overview of the 
scoring of the distress severity of the three surveyed gastrointestinal symptoms can be found. 
Statistical analysis of the distress severity of the three GI symptoms in the PP population 
demonstrated no difference between placebo and WBE treatment (P > 0.1, binary mixed 
model). 
DISCUSSION 
This study investigated, for the first time, the effect of WBE consumption in healthy 
preadolescent children (aged 8-12 years). The effects of WBE consumption at a dose of 5 
g/day on following gastrointestinal parameters were analyzed: faecal levels of microbiota, 
SCFAs, BCFAs, ammonia, faecal pH and faecal moisture. In addition, using self-reported 
scoring of the distress severity of three gastrointestinal symptoms, tolerance to WBE was 
assessed in children.  
WBE consumption by healthy children during 3 weeks at a daily dosage of 5 g led to an 
increase in faecal bifidobacteria levels, expressed as percentage of total microbiota, relative to 
placebo intake. These data extend earlier studies evaluating the effect of WBE and WBE-like 
material on faecal microbiota in healthy adult volunteers(7-9, 35), despite the fact that the 
relative level of faecal bifidobacteria in preadolescent children is higher than in adults(24). As 
was also observed in adult volunteers, intake of WBE by children only modulated faecal 
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levels of Bifidobacteria. The levels of the other bacterial groups analyzed, i.e. the 
Lactobacillus/Enterococcus group, the Clostridium histolyticum/lituseburense group, the 
Faecalibacterium prausnitzii group and the Roseburia/Eubacterium rectale group, were not 
modulated upon WBE intake. This points to a selective increase of faecal bifidobacteria levels 
relative to total faecal microbiota, upon WBE intake by healthy children.  
Beneficial effects of bifidobacteria on host health have been demonstrated through placebo-
controlled clinical trials involving direct oral supplementation with viable bifidobacteria.  For 
instance, oral intake of bifidobacteria by healthy infants was shown to lower the risk of 
experiencing respiratory infections(36). In addition, studies performed on patients suffering 
mild to moderate irritable bowel syndrome showed that supplementation with bifidobacteria 
improves symptoms of abdominal pain/discomfort, distension/bloating, and bowel movement 
difficulty(37,38). The mechanisms responsible for such effects have not been fully elucidated, 
yet may involve modification of the gut microbiota, competitive adherence to the intestinal 
mucosa and epithelium, strengthening of the gut epithelial barrier, and/or modulation of the 
immune system through interaction with pattern recognition receptors on gut epithelial 
cells(39). 
Intake of 5 g/d WBE resulted in a marked reduction of the faecal levels of BCFAs isobutyric 
acid and isovaleric acid by 28% as compared to the faecal BCFAs levels after placebo intake. 
BCFAs are not produced by human enzymes and are therefore unique bacterial metabolites. 
Isobutyric acid and isovaleric acid are produced from the fermentation of valine and leucine, 
respectively(40). As a consequence, excretion of BCFAs is often considered as a marker for the 
degree of protein fermentation in the colon(41). The reduction in protein fermentation observed 
in this study confirms previous results in adults, which showed a reduction in urinary and 
faecal p-cresol(7,8,10) or a beneficial modulation of the colonic ammonia metabolism (both 
protein fermentation metabolites)(42) after intake of WBE or WBE-like material. Colonic 
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fermentation of proteins results in the formation of ammonia, nitrosamines, thiols and 
phenolic compounds, which are generally believed to be potentially harmful. Hence, 
reduction of colonic protein fermentation is believed to be beneficial to human health(43). 
Consumption of 5 g/day WBE did not result in increased faecal levels of the carbohydrate 
fermentation products acetate, propionate and butyrate. François and co-workers showed 
increased faecal levels of these SCFAs after intake of 10 g/day WBE in healthy adults, but not 
after intake of 3 g/day WBE(8). The fact that an increase in faecal SCFA levels was not 
observed could be due to the intake of a WBE dose that was too low to modulate faecal SCFA 
levels. However, it should be kept in mind that faecal SCFA levels are the result of both 
colonic SCFAs production and mucosal absorption of these SCFAs(44). As such, the absence 
of increased faecal SCFA levels does not exclude an increased colonic fermentation following 
WBE fermentation.  
Intake of 5 g/d WBE by healthy children did not affect stool frequency, stool consistency or 
the composite Bristol measure. In addition, 5 g/ day WBE consumption did not have an effect 
on any of the three surveyed gastrointestinal symptoms: flatulence, abdominal pain/cramps, 
urge to vomit. In healthy adult volunteers, a mild increase of flatulence was observed at 10 
g/d WBE intake(11). Mild to moderate flatulence is observed in studies with other prebiotic 
compounds such as inulin and fructooligosaccharides, which is caused by the production of 
gases upon fermentation of the prebiotic compound(45-49).  
The low incidence of GI complaints together with the absence of a difference between the 
placebo and WBE treatment in occurrence frequency of the AE categories provides evidence 
for the excellent tolerability and safety of WBE in children. This is important since addition 
of WBE to food products intended for children may be a way to increase the fiber intake by 
these children. Indeed, intake data from the USA indicate that dietary fiber consumption is 
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inadequate in most children, especially from low-income and minority backgrounds(50). In this 
respect, it is also important to note that WBE is water-soluble and does not have a pronounced 
taste which makes it easy to formulate in food products without affecting their texture or taste. 
Other fiber sources, such as insoluble fibers, can disturb the taste or texture of a food product 
and thereby make it less attractive for consumption, in particular by children. 
In conclusion, intake of 5 g/d WBE exerts beneficial effects on gut parameters, in particular 
reduction of colonic protein fermentation and increase of relative faecal bifidobacteria levels. 
Moreover, WBE is well tolerated and does not cause adverse effects at up to 5 g/d in healthy 
children. 
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FIGURE & Table Legends 
FIGURE 1. Schematic representation of the study design. The study started with a one-week 
run-in (RI) period, followed by two 3-week treatment periods in which Wheat Bran Extract 
(WBE) was taken in by the subjects at a dose of 0 g/d (placebo) or 5 g/d (with the order 
differing between the two randomisation groups). The treatment periods were separated by a 
wash out (WO) period. Faecal samples were taken at different, indicated time points. During 
the run-in period and the last week of both treatment periods, the subjects completed daily a 
questionnaire assessing the distress severity of flatulence, urge to vomit and abdominal 
pain/cramps. Additionally, subjects recorded in the Bowel Habits Diary the number of bowel 
movements and stool consistency during the one-week run-in period and during the last week 
of each 3-week treatment period. RI = run-in; WO = wash out; GI = gastrointestinal. 
FIGURE 2. Volunteer disposition in the study. 
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TABLE 1. Characterization of the WBE preparation 
Constituent 
Concentration  
(% of dry matter) 
Arabinoxylan-oligosaccharides (AXOS) 79.0 
of which xylo-oligosaccharides (XOSDP3-9) 39.5 
of which xylobiose (XOSDP2) 22.2 
Glucuronic acid bound to AXOS 1.0 
Ferulic acid bound to AXOS 1.5 
Glucose (as part of poly/oligosaccharides) 12.2 
Galactose (as part of poly/oligosaccharides) 1.5 
Total free monosaccharides 0.5 
Protein (N x 6.25) 0.6 
Total lipids <0.5 
Ash 0.2 
Dry matter (%) 96.4 
DP = degree of polymerization 
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TABLE 2. Baseline data of the EE/PP population of children participating to the study 
  Gender Age (years) Stool 
frequency 
Bifidobacteria 
(log10 cells/g dry 
faeces) 
Randomisation 
group 
Subjects 
(No) 
Female 
(No) 
Male 
(No) Mean SD Mean SD Mean SD 
1 14 4 10 9.86 1.46 1.06 0.55 9.05 0.55 
2 14 6 8 9.79 1.19 1.00 0.43 8.72 0.34 
All 28 10 18 9.82 1.31 1.03 0.09 8.89 0.48 
Test statistic  0.701 0.812 0.962 0.0683
1 Fisher’s Exact Test for Count Data test 
2 Mann-Whitney U-test 
3 One-Way ANOVA 
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TABLE 3. Efficacy variables during the intervention study follwing intake of placebo and 5 g/d WBE. P is the p-value for the pairwise comparison between 5 
g/d WBE and placebo 
 Placebo treatment period 5 g/d treatment period  
 Mean SD Mean SD P 
Levels of faecal microbiota      
Total bacteria (log10 cells/g dry faeces) 10.79 0.41 10.74 0.34 0.403 
Bifidobacteria (log10 cells/g dry faeces) 9.17 0.47 9.36 0.41 0.069 
Percentage Bifidobacteria 3.25 2.66 5.67 3.89 0.002 
Lactobacilli (log10 cells/g dry faeces) 5.73 2.20 5.98 2.04 0.962 
F. prausnitzii (log10 cells/g dry faeces) 9.32 0.73 9.35 0.49 0.843 
C. histolyticum/lituseburense (log10 cells/g dry faeces) 3.52 1.77 3.14 1.19 0.390 
Roseburia/Eubacterium rectale (log10 cells/g dry faeces) 8.97 1.79 8.99 1.67 0.979 
Biochemical parameters of faeces      
Acetic acid (µmol/g dry faeces) 357.44 210.85 348.61 110.68 0.845 
Propionic acid (µmol/g dry faeces) 79.61 47.54 78.65 40.41 0.915 
Butyric acid (µmol/g dry faeces) 84.18 55.15 67.83 33.25 0.143 
Total SCFAs1 (µmol/g dry faeces) 521.23 292.82 495.09 160.68 0.791 
Isobutyric acid (µmol/g dry faeces) 11.37 6.10 8.10 3.94 0.005 
Isovaleric acid (µmol/g dry faeces) 14.36 7.76 10.55 5.62 0.008 
Total BCFAs2 (µmol/g dry faeces) 25.74 13.81 18.65 9.52 0.006 
Stool pH 7.28 0.58 7.05 0.82 0.110 
Stool moisture (%) 72.03 6.41 70.04 5.89 0.230 
Ammonia (mg/g dry faeces) 2.21 0.81 2.25 1.06 0.874 
Bowel habits      
Stool frequency (# bowel movements/day) 0.99 0.65 0.99 0.53 1.000 
Stool consistency (average stool consistency/bowel movement) 3.36 0.96 3.01 0.82 0.308 
Bristol composite measure (average stool consistency/day) 2.50 1.27 2.41 1.07 0.775 
1 Total SCFAs levels are defined as the sum of the levels of acetic acid, propionic acid and butyric acid; 
2 Total BCFAs levels are defined as the sum of the levels of isobutyric acid and isovaleric acid. 
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TABLE 4. Overview of the scoring of the three surveyed gastrointestinal symptoms 
  Placebo treatment period 5 g/d WBE treatment period 
GI symptom Average score1 Number2 Percentage3 Number Percentage 
Abdominal 
pain 
0 20 71 17 61 
> 0 -0.5 6 21 7 25 
> 0.5 - 1 2 7 3 11 
> 1 - 1.5 1 4 1 4 
Urge to vomit 0 27 96 27 96 > 0 -0.5 1 4 1 4 
Flatulence 
0 13 46 11 39 
> 0 -0.5 8 29 7 25 
> 0.5 - 1 5 18 7 25 
> 1 - 1.5 1 4 2 7 
> 1.5 - 2 1 4 1 4 
1 The average score is the average for the 7 days period during which symptoms were surveyed; 
2 The number of volunteers with a specified average gastrointestinal (GI) symptom severity score is 
shown for each treatment; 
3 The percentage of volunteers with a specified average GI symptom severity score is shown 
(denominator for the calculation of the percentage is the number of volunteers in the specified 
treatment period). 
 
